Short answer
PULSE BIOSCIENCES, INC. (PLSE) filed an 8-K current report with the SEC on May 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 8.01 (Other Events). Forward-looking statements cover anticipated financial reports, operating results, expenses, financial position, and cash flows.
PULSE BIOSCIENCES, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Forward-looking statements cover anticipated financial reports, operating results, expenses, financial position, and cash flows
- Actual results may differ materially from management expectations, increasing execution and forecasting risk
- Investors should assess projections alongside PLSE’s latest Form 10-K risk factors
Item 8.01 · Other Events
- Accelerated NANOPULSE-AF enrollment potentially shortens timeline toward pivotal readouts for nPulse cardiac catheter system
- Approximately 215 participants planned across multiple sites for recurrent, drug-resistant symptomatic paroxysmal AF
- Primary endpoints assessed at 6 and 12 months post-ablation, covering procedural success and safety
- NANOCLAMP-AF enrollment expected complete by end of first half 2027 for concomitant surgical AF treatment
- International site participation expands NANOCLAMP-AF trial reach, including two sites outside the United States
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other PULSE BIOSCIENCES, INC. 8-K filings
Get the next PLSE 8-K as it lands
Follow PLSE for push alerts, or ask the research agent what this filing means.